ALNY
Alnylam PharmaceuticalsPrevious close
227.02
Change
−5.66 / −2.43%
P/E (TTM) ?
38.5
Market Cap
$31.1B
1M
−8.71%
S&P 500 +1.81% over same period
Volume / Avg Volume
917K / 1.3M
0.69× average
Latest earnings analysisFY2026 Q2Reported 2026-07-30
Alnylam Q2 2026: revenue up 67.0%, EPS beat, TTR guidance cut
Alnylam delivered a strong quarter with a softer full-year message: revenue rose 67.0% to $1.29 billion and non-GAAP EPS of $1.84 beat the $1.5858 consensus, yet management cut full-year TTR product sales guidance to $4.2–$4.5 billion. Read this as a launch finding its real growth rate after an early phase flattered by pent-up demand, not as a business losing its franchise.
Read the full analysis →Revenue$1.29BYoY +66.90%
EPS (non-GAAP)$1.84Beatest. $1.59
Next-quarter revenue guidance$4.90B ±4.08%YoY +279.60%
Next-day move+0.02%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-30 | $1.3B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-30 | $1.2B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-12 | $3.7B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-30 | $1.2B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-31 | $774M | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-05-01 | $594M | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
A 5-year P/E range needs a longer earnings record; not yet comparable
No buybacks or dividends in the last four quarters
P/E (TTM)
38.5
P/B
23.0
P/S
6.5
PEG
0.43
Earnings Reaction
Over the last 6 reports, the stock moved ±1.7% on average on the first trading day after, rising 4 times
Most recent +0.02%
Volatility & Correlation
1-year beta -0.09 · Correlation with S&P 500 -0.02Low beta
Annualized volatility 57% vs. 12% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 1 · $0.40MNet selling $0.40M
- 10-02SUPRAN BRYANEVP, CLO and SecretarySell$0.40M1,758 shares · Avg price 226.88
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 1.29 | +66.9% | 76.9% | 0.16 | 1.21 |
| FY2025 Q4 | 1.10 | +84.9% | 75.6% | 0.15 | 1.18 |
| FY2025 Q3 | 1.25 | +149.3% | 84.2% | 0.25 | 1.84 |
| FY2025 Q2 | 0.77 | +17.3% | 81.6% | -0.07 | -0.55 |
| FY2025 Q1 | 0.59 | +20.2% | 88.2% | -0.02 | -0.14 |
| FY2024 Q4 | 0.59 | +34.9% | 82.7% | -0.08 | -0.66 |
| FY2024 Q3 | 0.50 | −33.3% | 83.6% | -0.11 | -0.87 |
| FY2024 Q2 | 0.66 | +107.0% | 89.8% | -0.02 | -0.13 |
| FY2024 Q1 | 0.49 | +54.8% | 89.0% | -0.07 | -0.52 |
| FY2023 Q4 | 0.44 | +31.2% | 83.6% | -0.14 | -1.06 |
| FY2023 Q3 | 0.75 | +184.0% | 89.4% | 0.15 | 1.15 |
| FY2023 Q2 | 0.32 | +41.8% | 76.4% | -0.28 | -2.21 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| ALNY | 38.5 | +66.9% | 76.9% | −8.71% | Neutral |
| LLY | 41.6 | +47.7% | 85.8% | +6.00% | Bullish |
| JNJ | 29.9 | +6.6% | 68.2% | −0.70% | Bullish |
| ABBV | 77.4 | +10.2% | 74.7% | +9.33% | Bullish |
| MRK | 113.2 | +5.1% | 73.5% | +1.06% | Neutral |
| UNH | 24.1 | +0.4% | 88.1% | −0.15% | Bullish |
| TMO | 34.9 | +10.5% | — | +8.60% | Neutral |
| AMGN | 25.7 | +9.5% | 72.0% | +10.66% | Bullish |
| GILD | — | +10.2% | 79.8% | +4.67% | Neutral |